@Tunpika. melibatkan semua. Inbound dan outbond travelers. So many countries around the world. I think Nexgram is the sole company who will serve goverment using its TracvirusSafeTravelPass
Harap-harap Dato Yek ada duit banyak, belilah banyak sikit dari Ozura. He He. Saja............. nak tunggu berita positif sahaja. Oh Ya, mana OKU_2020 hari ni....
Agree with you Tunpika. Dato Yek's action concerning his intention to deal in this company's stock during closed period is interesting to wait. For me, it will be a good or bad signal about the company as a whole.
If proceeded to buy, very very good. If proceeded to sell, bad.
Mau limit up sume kena sabar, kena hold tight tight maaa, jgn panic selling bila turun sikit.. naik ke. Ozura bukan ape, dia mau cukup target sajeee untuk skarang niiii. Bila dah ckup target tengok nanti next week....zupppp limit up....sabarrr sape tak mau limit up.
@David Coperfield. Sorry to differ. I have a good record about this.
255,100,000 unit - current balance up to Nov 16th disposal (baki syer selepas jualan pada 16 Nov + 37,189,697 unit (unconverted ICPS means ICPS belum ditukar jadi syer) = 292,289,697 unit
Tak berapa boleh percaya juga Dato Yek. Terkini pada 21/8/2020 ada juga annoucement untuk deal during closed period, tapi apa yang ada selepas itu dia hanya beli beberapa kali dalam jumlah yang kecil. To be transparent. Tapi saya betul harap kali ini pengemuman itu ada kaitan dengan syer Ozura. Macam-macam mimpi ada bila saya jadi pelabur kecil Nexgerammmm. He He
Dengan harga 0.055sen x 290000lot akan me libatkan kewangan sebanyak kurang lebih rm16 juta. Pendapat saya pembelian during close period tak mungkin berlaku.
@saif9545. Selepas pengumuman intention nak deal closed period pada 21/8/20 hari tu, Dato Yek beli saham sebanyak 8-9 kali tetapi semuanya via open market. Bermakna tiada deal closed period walaupun sedikit.
Ini kali tak tahulah. Itu saya kata kalau jadi deal beli walaupun sedikit/sebahagian sahaja sangat sangat sangat memberi konotasi yang baik kepada saya tentang prospek syarikat.
China Sinopharm's coronavirus vaccine taken by about a million people in emergency use No serious adverse reaction has been reported from those who received the vaccine in emergency use, Sinopharm said in an article on social media WeChat, citing Chairman Liu Jingzhen from a recent media interview. China Sinopharm's coronavirus vaccine taken by about a million people in emergency use A sign of Sinopharm is seen at the 2020 China International Fair for Trade in Services (CIFTIS), following the Covid-19 outbreak, in Beijing, China September 5, 2020. Reuters File Photo
bookmark facebook twitter mail Reuters Published at : November 19, 2020Updated at : November 19, 2020 18:10Beijing Nearly one million people have taken an experimental coronavirus vaccine developed by China National Pharmaceutical Group (Sinopharm) through the country’s emergency use programme, the firm said late on Wednesday.
China launched the emergency use programme in July, which so far includes three vaccine candidates for essential workers and other limited groups of people even as clinical studies have yet to be completed to prove their safety and efficacy.
No serious adverse reaction has been reported from those who received the vaccine in emergency use, Sinopharm said in an article on social media WeChat, citing Chairman Liu Jingzhen from a recent media interview.
Two vaccine candidates developed by Sinopharm's subsidiary China National Biotec Group (CNBG) and third one developed by Sinovac Biotech SVA.O have been used for the emergency programme.
It’s unclear which vaccine Liu referred to, and Sinopharm was not immediately available to comment.
Sinopharm’s vaccines, which use inactivated virus unable to replicate in human cells to trigger immune responses, require two doses, clinical trial registration data showed.
The experimental vaccines are undergoing Phase 3 clinical trials overseas that have recruited nearly 60,000 people, and blood samples of more than 40,000 participants have been taken 14 days after they took the second dose, the article said citing Liu, without breaking down the numbers for each vaccine.
@MZM 2511 Pada hemat saya semuanya boleh. Ia melibatkan jutaan ringgit. Sedangkan bermula 21/8 dengan belian sebanyak 8/9 kali pun jumlah saham dibeli tidak melebihi 1000lot
Semua dibeli via open market dan tiada closed period. Apa intention dia buat announcement tersebut??? NAK COVER OZURA KE NAK COVER PEMEGANG SAHAM LAIN ???
WORLD Sinovac's COVID-19 vaccine induces quick immune response: study The study comes hot on the heels of upbeat news this month from U.S. drugmakers Pfizer and Moderna as well as Russia that showed their experimental vaccines were over 90% effective based on interim data from large, late-stage trials. Sinovac's COVID-19 vaccine induces quick immune response: study Reuters
Published at : November 18, 2020Updated at : November 18, 2020 15:44 Sinovac Biotech’s experimental COVID-19 vaccine CoronaVac triggered a quick immune response but the level of antibodies produced was lower than in people who had recovered from the disease, preliminary trial results showed on Wednesday.
While the early to mid-stage trials were not designed to assess the efficacy of CoronaVac, researchers said it could provide sufficient protection, based on their experience with other vaccines and data from preclinical studies with macaques.
The study comes hot on the heels of upbeat news this month from U.S. drugmakers Pfizer and Moderna as well as Russia that showed their experimental vaccines were over 90% effective based on interim data from large, late-stage trials.
CoronaVac and four other experimental vaccines developed in China are currently undergoing late-stage trials to determine their effectiveness in preventing COVID-19.
The Sinovac findings, published in a peer-reviewed paper in medical journal The Lancet Infectious Diseases, came from results in Phase I and Phase II clinical trials in China involving more than 700 participants.
“Our findings show that CoronaVac is capable of inducing a quick antibody response within four weeks of immunisation by giving two doses of the vaccine at a 14-day interval,” Zhu Fengcai, one of the authors of the paper, said.
“We believe that this makes the vaccine suitable for emergency use during the pandemic,” Zhu said in a statement published alongside the paper.
Researchers said the findings from large, late-stage studies, or Phase III trials, would be crucial to determine if the immune response generated by CoronaVac was sufficient to protect people from the coronavirus infection.
Sinovac is currently running three Phase III trials in Indonesia, Brazil and Turkey.
The results must be interpreted with caution until Phase III results are published, Naor Bar-Zeev, a professor from Johns Hopkins University who was not involved in the study, said.
“But even then, after Phase III trial completion and after licensure, we should prudently remain cautious,” he said.
‘ATTRACTIVE OPTION’
CoronaVac is one of three experimental COVID-19 vaccines China has been using to inoculate hundreds of thousands of people under an emergency use programme.
The two other vaccines in China’s emergency programme, both developed by institutes linked to Sinopharm, and another vaccine from CanSino Biologics, were also shown to be safe and triggered immune responses in early and mid-stage trials, peer-reviewed papers show.
Gang Zeng, a Sinovac researcher involved in the CoronaVac study, said the vaccine could be an attractive option because it can be stored at normal fridge temperatures of 2 to 8 degrees Celsius (36°-46°F) and may remain stable for up to three years.
“(It) would offer some advantages for distribution to regions where access to refrigeration is challenging,” the author said.
Vaccines developed by Pfizer/BioNTech and Moderna use a new technology called synthetic messenger RNA (mRNA) to activate the immune system against the virus and require far colder storage.
Pfizer’s vaccine must be stored and transported at -70C though it can be kept in a normal fridge for up to five days, or up to 15 days in a thermal shipping box. Moderna’s candidate is expected to be stable at normal fridge temperatures for 30 days but for storage of up to six months it needs to be kept at -20C.
CoronaVac is also being considered by Brazil and Indonesia for inoculations in the coming months.
Indonesia has sought emergency authorisation to start a mass vaccination campaign by the end of the year and vaccines produced by Sinovac and China’s Sinopharm are slated to be used in the early stages of the campaign.
Brazil’s Sao Paulo also plans to roll out CoronaVac as early as January and has agreed a supply deal with Sinovac.
November is best month for Nexgram to fly high, lepas tu dah lambat. My darling Nexgram, I dah tunggu 5 bulan tapi tak naik2. Tapi skrang u dah ade competitors Mtouche, dia lagi shantik, lagi muda,future ade, dah inked agreements petang tadi. NEXGRAM u tak jage u punyer cuttinggg I cabut ....babaiii.
Okay, Enough is enough. Yesss. No Sweat... Go Go Go Nexgrammmmmm
SEMUT YANG BANYAK BOLEH MENGALAHKAN GAJAH
Magnificient achievement from Nexgram: Tracvirus4Malaysia NexgramBottleVaccine Tracvirus with tracking vaccination is ready and Covid-19 vaccine distri................ (a possibility)
[Exclusive] 1.3 million foreign workers need to be tested for coronary disease social insurance if employers are willing to cooperate November 19, 2020 Exclusive report: Pan Liting / Nanyang Siang Pau
Conclusion: I have many reasons to DREAM that Nexgram has many capabilities to be involve in Covid-19 VACCINE businesses because of their readiness with: 1. Tracvirus (involving covid-19 testing and also can be used in tracking online about individual covid-19 vaccination information), 2. Their subsidiary also involve in vaccine activities, 3. Their subsidiary's ability to produce and supply vaccine bottles 4. Their close contact with MOH
REPOSTING; @m-faiza1. also Tracvirus which is also ready for tracking/management of vaccination record online.
.....“Vaccine bottles using Arita Covid-19 vaccine plastic sheet came with Tracvirus vaccine record tracking App, a global unified electronic certification (E-Cert) for International travel, social, work and school Covid-19 test and vaccine record anti-fraud and anti-fake verification solution,” the firm added.,,,,,
SafeTravelPass is officially accepted to collect payment for government agencies for inbound travellers Covid-19 Screening Test, Quarantine, and Vaccine tracing in Malaysia.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
MZM2511
4,549 posts
Posted by MZM2511 > 2020-11-19 21:39 | Report Abuse
@Tunpika. melibatkan semua. Inbound dan outbond travelers. So many countries around the world. I think Nexgram is the sole company who will serve goverment using its TracvirusSafeTravelPass